Log in to search using one of your social media accounts:

 

Computer program finds new uses for old drugs
(Case Western Reserve University) Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy. In a recent study published in Oncogene, the researchers successfully translated DrugPredict results into the laboratory, and showed common pain medications--like aspirin--can kill patient-derived epithelial ovarian cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2017 Category: Cancer & Oncology Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Surveillance safe for non-cancerous breast lesion typically treated surgically
(American College of Surgeons) The detection of certain non-cancerous 'high risk' breast lesions can lead to surgical treatment in women, but one of the largest studies of a specific type of high-risk lesion, flat epithelial atypia, calls for close observation, rather than surgical removal of these lesions in most cases, according to study results published on the website of the Journal of the American College of Surgeons in advance of print. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2017 Category: Cancer & Oncology Source Type: news

Papers of note in Nature 550 (7677)
This week’s articles highlight inflammatory memory in epithelial stem cells; ubiquitin-specific protease inhibitors that target cancer cells; the identification of a sphingosine 1-phosphate exporter; and G protein signaling hotspots on the plasma membrane. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 31, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news

Study finds N-alpha-acetyltransferase D (NatD) promotes lung cancer progression
(Nanjing University School of Life Sciences) Researchers at Nanjing University and their collaborators have found that NatD, which mediates N-alpha-terminal acetylation (Nt-acetylation) of histone H4, promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate the transcription factor Slug, a key regulator of the epithelial-to-mesenchymal transition (EMT). Their study results are published in the Oct. 13, 2017, issue of the journal Nature Communications. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2017 Category: Biology Source Type: news

Aggressive Mesothelioma Surgery Benefits More Patients
Patients diagnosed with the worst cases of pleural mesothelioma could benefit the most from the aggressive surgery they often are denied, according to one recent study. The findings have raised questions about the restrictive surgery selection process at many specialty centers handling mesothelioma, the rare and aggressive cancer caused by asbestos exposure. “In some cases, patients are not being offered the aggressive surgery that could help their quality of life,” lead author Dr. Wickii Vigneswaran, mesothelioma specialist and chief of thoracic surgery at the Loyola University Medical Center, told Asbestos.co...
Source: Asbestos and Mesothelioma News - October 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Aggressive Mesothelioma Surgery asbestos exposure Dr. Wickii Vigneswaran epithelial mesothelioma epithelioid histology extrapleural pneumonectomy Loyola mesothelioma program Loyola University Medical Center mesothelioma Chicago mesotheli Source Type: news

Qiagen Partners with Cell Diagnostics Company
ANGLE plc, a liquid biopsy company, has secured a valuable partnership with molecular testing giant Qiagen and an exclusive option agreement with Queen Mary University of London. ANGLE is known for Parsortix, its novel system for capturing and harvesting circulating tumor cells (CTCs) from blood. A Large Selling Opportunity with Qiagen The co-marketing partnership with Qiagen isn’t just a major win for ANGLE—it will also give Qiagen, which has more than 500,000 customers, an additional opportunity in the liquid biopsy space and the ability to offer ANGLE’s unique CTC harvesting technology alongside its ow...
Source: MDDI - September 19, 2017 Category: Medical Devices Authors: Marie Thibault Tags: IVD Source Type: news

Regulation of autophagy, NF-{kappa}B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells
KRAS mutant non–small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of the RAS pathway. Identifying alternative networks that promote survival specifically in mesenchymal NSCLC may lead to more effective treatments for this subtype. Through their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate the epithelial-mesenchymal transition (EMT...
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Mehta, A. K., Hua, K., Whipple, W., Nguyen, M.-T., Liu, C.-T., Haybaeck, J., Weidhaas, J., Settleman, J., Singh, A. Tags: STKE Research Articles Source Type: news

Mesothelioma Patients Survive Longer with Trimodal Treatment
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - September 5, 2017 Category: Environmental Health Authors: Matt Mauney Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news

New insight into how excess belly fat may increase cancer risk
Conclusion This animal and laboratory study investigated the possible cellular relationship between excess body fat – specifically fat around the body organs – and cancer risk. It seems one key mechanism by which excess visceral fat could stimulate healthy cells to develop into cancerous ones could be through FGF2 levels. The researchers hope their study could pave the way for possible cancer prevention strategies by stopping FGF2 production in obese people with excess belly fat. They even go as far as suggesting that blocking FGF2 receptors could be one part of a treatment approach after a diagnosis of breas...
Source: NHS News Feed - September 1, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer
Androgen deprivation therapy (ADT) targeting the androgen receptor (AR) is a standard therapeutic regimen for treating prostate cancer. However, most tumors progress to metastatic castration-resistant prostate cancer after ADT. We identified the type 1, 2, and 4 collagen–binding protein transforming growth factor–β (TGFβ)–induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition (EMT) and malignant progression of prostate cancer. In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression o...
Source: Signal Transduction Knowledge Environment - August 15, 2017 Category: Science Authors: Chen, W.-Y., Tsai, Y.-C., Yeh, H.-L., Suau, F., Jiang, K.-C., Shao, A.-N., Huang, J., Liu, Y.-N. Tags: STKE Research Articles Source Type: news

Cytology versus HPV testing for cervical cancer screening in the general population: a DTA Review from the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Group, (CGNOC)
Cochrane Reviews are systematic reviews of research in health care and policy. They are internationally recognized as a high-quality source of evidence for decision-making. They collate and summarize all the best available research evidence on the effects of healthcare interventions or the accuracy of diagnostic tests into a systematic review.Diagnostic Test Accuracy Reviews (DTA) provide essential information regarding the accuracy of the available diagnostic tools for key decision makers, including patients, clinicians, guideline developers and researchers.  The purpose of a Cochrane DTA review is very like the purp...
Source: Cochrane News and Events - August 14, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Gene editing brings pig organ transplant closer
Conclusion This promising research shows that it can be possible to use gene editing techniques to eliminate retroviruses from pigs, removing one of the potential barriers to using genetically modified pigs as organ donors for humans. There are a few points to note. As the researchers say, though they have shown that pig retroviruses can be passed onto human cells in the laboratory, we don't know what the effects would be in real life. We don't know whether pig retroviruses would be transferred to humans and whether they could cause cancers or immunodeficiency illnesses, for example. The research is at an early stage. The ...
Source: NHS News Feed - August 11, 2017 Category: Consumer Health News Tags: Genetics/stem cells Source Type: news

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy
(Tokyo Medical and Dental University) TMDU researchers revealed that, in pancreatic cancer, the microRNAs miR-509-5p and miR-1243 can promote E-cadherin expression and thereby reduce the likelihood of cells undergoing epithelial-mesenchymal transition, or indeed reverse this transition. This ability to stop cells from adopting a phenotype linked to high migration and invasiveness was also shown to synergistically increase the cancer cell-killing efficacy of gemcitabine, which is promising for developing more effective combinatorial treatments for pancreatic cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 1, 2017 Category: Cancer & Oncology Source Type: news

ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b
Metastasis is a multistep process by which tumor cells disseminate from their primary site and form secondary tumors at a distant site. The pathophysiological course of metastasis is mediated by the dynamic plasticity of cancer cells, which enables them to shift between epithelial and mesenchymal phenotypes through a transcriptionally regulated program termed epithelial-to-mesenchymal transition (EMT) and its reverse process, mesenchymal-to-epithelial transition (MET). Using a mouse model of spontaneous metastatic breast cancer, we investigated the molecular mediators of metastatic competence within a heterogeneous primary...
Source: Signal Transduction Knowledge Environment - June 13, 2017 Category: Science Authors: Zhou, W., Ye, X.-l., Xu, J., Cao, M.-G., Fang, Z.-Y., Li, L.-Y., Guan, G.-H., Liu, Q., Qian, Y.-H., Xie, D. Tags: STKE Research Articles Source Type: news

An elegans solution: Worm genetic screen maps cell-to-cell communication in human cancer
(Medical University of South Carolina) In the May 22, 2017, issue of Developmental Cell, researchers at the Medical University of South Carolina Hollings Cancer Center developed a cross-species genetic screen in worms to follow cell-to-cell communication in human cancer. The genome-wide screen is being used to chart a roadmap between mesodermal cells and epithelial cells in the tumor microenvironment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 22, 2017 Category: Cancer & Oncology Source Type: news

Moffitt Opens Mesothelioma Study for Rare Cancer Subtypes
The Moffitt Cancer Center in Tampa has opened a mesothelioma clinical trial involving an anti-cancer enzyme drug showing unprecedented success with the most difficult disease subtypes. Patients with sarcomatoid and biphasic histology — the most treatment-resistant subtypes of mesothelioma — can now enroll in a phase 2/3 clinical trial involving the effectiveness of ADI-PEG 20 (pegylated arginine deiminase) in combination with standard chemotherapy. Thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center at Moffitt, told Asbestos.com that he and fellow investigators are ...
Source: Asbestos and Mesothelioma News - April 25, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: doctor jacques fontaine improving mesothelioma prognosis mesothelioma chemotherapy with cisplatin mesothelioma clinical trial mesothelioma treatments moffitt cancer center Source Type: news

Epithelial Proliferation in Biopsies Tied to Breast Cancer Risk Epithelial Proliferation in Biopsies Tied to Breast Cancer Risk
Women with progressive epithelial proliferation across serial biopsies have an increased risk of breast cancer, while those with regression of initial proliferative disease without atypia face a lower risk compared with no change.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

[Report] Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display prefere...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Sanja Stevanovi ć Source Type: news

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display prefere...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Stevanovic, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., Hinrichs, C. S. Tags: Immunology reports Source Type: news

The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat. For example, the transforming growth factor–β (TGF-β) pathway is implicated in TNBC progression and metastasis, but its opposing role in tumor suppression in healthy tissues and early-stage lesions makes it a challenging target. Therefore, additional molecular characterization of TNBC may lead to improved patient prognosis by informing the development and optimum use of targeted therapies. We found that musculoaponeurotic fibrosarcoma (MAF) oncogene family protein K (MAFK), a member of the small MAF family of transcripti...
Source: Signal Transduction Knowledge Environment - April 11, 2017 Category: Science Authors: Okita, Y., Kimura, M., Xie, R., Chen, C., Shen, L. T.-W., Kojima, Y., Suzuki, H., Muratani, M., Saitoh, M., Semba, K., Heldin, C.-H., Kato, M. Tags: STKE Research Articles Source Type: news

Survival Similar With Debulking by Laparotomy, Laparoscopy
Similar three - year survival rates for women with epithelial ovarian cancer undergoing debulking (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 10, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Surgery, Journal, Source Type: news

FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news

Hitting cancer with high-intensity ultrasound, immunotherapy
In a new study, researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news

Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Hormonal maintenance therapy may improve survival in women with rare serous carcinoma
For women with a rare subtype of chemo-resistant epithelial ovarian or peritoneum cancer, hormone maintenance therapy may significantly improve survival, according to a new study in theJournal of Clinical Oncology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 22, 2017 Category: Science Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peri
(University of Texas M. D. Anderson Cancer Center) For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2017 Category: Cancer & Oncology Source Type: news

PID and the Risk of Ovarian Cancer and Borderline Tumors PID and the Risk of Ovarian Cancer and Borderline Tumors
Is there a link between pelvic inflammatory disease and the risk of epithelial ovarian cancer or other ovarian tumors?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Scientists discover how epithelial cells maintain constant cell numbers
(University of Utah Health Sciences) Research published today in Nature from scientists at Huntsman Cancer Institute (HCI) at the University of Utah shows how epithelial cells naturally turn over, maintaining constant numbers between cell division and cell death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2017 Category: Global & Universal Source Type: news

Scientists discover how the cells in skin and organ linings maintain constant cell numbers
(University of Utah Health Sciences) Research published today in Nature from scientists at Huntsman Cancer Institute (HCI) at the University of Utah shows how epithelial cells naturally turn over, maintaining constant numbers between cell division and cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 15, 2017 Category: Cancer & Oncology Source Type: news

Surprise advance in the treatment of adult cancers
An epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use was identified. This discovery was unexpected since it seemed highly improbable that this kind of alterations of the epigenome found in children could also target an epithelial tumor like throat cancer that occurs only in adults. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2017 Category: Science Source Type: news

A surprise advance in the treatment of adult cancers
(McGill University Health Centre) An epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use was identified. This discovery was unexpected since it seemed highly improbable that this kind of alterations of the epigenome found in children could also target an epithelial tumor like throat cancer that occurs only in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news

[Report] SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer
Some cancers evade targeted therapies through a mechanism known as lineage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no longer depends on the drug target. We use in vitro and in vivo human prostate cancer models to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor (AR)–dependent luminal epithelial cells to AR-independent basal-like cells. This lineage plasticity is enabled by the loss of TP53 and RB1 function, is mediated by increased expression of the reprogramming transcription fa...
Source: ScienceNOW - January 5, 2017 Category: Science Authors: Ping Mu Source Type: news

Researchers identify new suppressor effects of the NOX4 protein in liver cancer
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers of IDIBELL and King's College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2016 Category: Cancer & Oncology Source Type: news

Study Shows Impact of Chemotherapy on Mesothelioma
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients. Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as age, gender and amount of asbestos exposure. Not only did the findings show mesothelioma patients who have chemotherapy live longer, but it also proved multimodal therapy increases survival even more. The s...
Source: Asbestos and Mesothelioma News - December 19, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma doctor shirish gadgeel first line treatment for mesothelioma Human Investigation Committee at Wayne State mesothelioma diagnosis peritoneal mesothelioma wayne state university Source Type: news

Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Media News)
Source: Roche Media News - December 7, 2016 Category: Pharmaceuticals Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2016 Category: Pharmaceuticals Source Type: news

Medical News Today: Cancer: Molecular insights into anti-tumor effects of diabetes drug
Study sheds new light at molecular level on how widely prescribed diabetes drug metformin protects epithelial barriers against stress and prevents tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2016 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
The metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial –mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. This finding highlights the value of targeting D-2HG to establish new therapeutic approaches against co lorectal cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news

Extending Late-Stage Mesothelioma Survival with Light Energy
Thoracic surgeon Dr. Joseph Friedberg and his colleagues identified a subset of patients with pleural mesothelioma who achieved a median overall survival of 7.3 years — an impressive survival compared to the usual one-year prognosis. The findings, which were published recently in The Annals of Thoracic Surgery, stemmed from a retrospective study that detailed significant progress in the fight against this incurable, asbestos-related cancer. The study included 73 patients with epithelioid mesothelioma who were treated at the Penn Medicine Abramson Cancer Center, where Friedberg practiced before taking the role of dire...
Source: Asbestos and Mesothelioma News - December 1, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: doctor joseph friedberg late stage mesothelioma stage 3 mesothelioma stage 4 mesothelioma stage III mesothelioma stage IV mesothelioma treatment for late stage mesothelioma treatment for pleural mesothelioma Source Type: news

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
(Osaka University) Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against colorectal cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 1, 2016 Category: Biology Source Type: news

Primary Surgery Tops Neoadjuvant Chemo in Epithelial Ovarian Cancer?
A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

Study Uncovers Strange Growth of Mesothelioma Tumors
A new analysis on how asbestos-related tumors grow may lead to more effective research and treatments of malignant mesothelioma. Researchers at Australia’s Flinders University found malignant mesothelioma tumors demonstrate vasculogenic (vascular) mimicry — the process in which tumors make their own blood vessels. Tumors promote their own growth by growing blood vessels that reach into surrounding tissues instead of waiting for the outside of the tissue to grow blood vessels into the cancer cells. Oxygen and nutrients from blood vessels allow cancer cells to develop into secondary tumors. “[Vasculogen...
Source: Asbestos and Mesothelioma News - November 29, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer tumor growth chemotherapy for mesothelioma growth of mesothelioma tumors how do mesothelioma tumors grow mesothelioma clinical trials mesothelioma research mesothelioma treatment mesothelioma tumor growth Source Type: news